Scancell Holdings ((GB:SCLP)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Scancell Holdings is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2, Multicentre, Open-Label Study of Modi-1 Moditope in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of the Modi-1 Moditope vaccine as both a standalone treatment and in combination with checkpoint inhibitors for various advanced cancers, including triple negative breast cancer and renal cell carcinoma.
The intervention being tested is the Modi-1 Moditope, a biological vaccine administered intradermally using the MicronJet600™ microneedle device. It is designed to stimulate an immune response against cancer cells, either alone or with checkpoint inhibitors like pembrolizumab.
This open-label, non-randomized study employs a parallel intervention model with no masking, focusing primarily on treatment. It involves multiple cohorts, including those receiving Modi-1 alone and in combination with standard care checkpoint inhibitors.
The study began on January 31, 2022, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on September 11, 2025, indicating ongoing recruitment and progress.
The update on this study could positively influence Scancell Holdings’ stock performance by enhancing investor confidence in its innovative cancer treatments. As the biotech industry is highly competitive, advancements in this study may also impact investor sentiment towards competitors working on similar therapies.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.